JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Search

Certara Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.17 0.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.12

Max

6.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.4M

-5.9M

Pardavimai

-968K

104M

P/E

Sektoriaus vid.

100.714

67.147

Pelno marža

-5.688

Darbuotojai

1,515

EBITDA

8.6M

32M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+44.07% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-77M

957M

Ankstesnė atidarymo kaina

5.35

Ankstesnė uždarymo kaina

6.17

Naujienos nuotaikos

By Acuity

50%

50%

186 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Certara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 23:08; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 23:07; UTC

Uždarbis

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:20; UTC

Uždarbis

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026-04-30 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026-04-30 23:27; UTC

Rinkos pokalbiai

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026-04-30 23:22; UTC

Uždarbis

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026-04-30 23:20; UTC

Rinkos pokalbiai

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026-04-30 22:52; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:33; UTC

Uždarbis

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026-04-30 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026-04-30 22:05; UTC

Uždarbis

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026-04-30 21:57; UTC

Uždarbis

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026-04-30 21:55; UTC

Uždarbis

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026-04-30 21:53; UTC

Uždarbis

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Akcijų palyginimas

Kainos pokytis

Certara Inc Prognozė

Kainos tikslas

By TipRanks

44.07% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  44.07%

Aukščiausias 10 USD

Žemiausias 7 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Certara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

3

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

11.27 / 12.79Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

186 / 347 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat